DOCSLIB.ORG

Mutational Landscape of ALL: Next-Generation Sequencing-Based Mutations Scanning Strategy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mutational Landscape of ALL: Next-Generation Sequencing-Based Mutations Scanning Strategy Mutational Landscape of ALL: Next-Generation Sequencing-based Mutations Scanning Strategy 15 Mar 2019 Seung-Tae Lee Dept. of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea WHO 2016 classification B-lymphoblastic leukemia Key genetic subtypes of B-ALL Iacobucci et al. J Clin Oncol 2017 Philadelphia-like ALL • Adverse prognosis • Responsiveness to TKIs • Peak incidence in young adults Iacobucci et al. J Clin Oncol 2017 Common genetic features of Ph-like ALL • Cytokine receptor and tyrosine kinase signaling – CRLF2 mutation (~ 50%) – ABL-class tyrosine kinase gene rearrangement (12%) – JAK2 rearrangement (7%) – EPOR rearrangement (3~10%) – JAK-STAT activating mutation (11%) – Ras signaling (NRAS, KRAS, PTPN11, and NF1; 6%) – kinase alterations (FLT3, NTRK3, BLNK, TYK2, and PTK2B) • B-lymphoid transcription factor genes – IKZF1 deletion Kinase Gene Fusions Philadelphia-like ALL Roberts et al. New Eng J Med. 2014 CRLF2 deregulation • Mutation type – IGH-CRLF2 translocation – P2RY8-CRLF2 fusion (by focal deletion upstream of CRLF2) – CRLF2 point mutations (F232C) • Associated features – Common in Ph-like and Down syndrome–associated ALL – Additional alterations in JAK-STAT (JAK1, JAK2), Ras signaling genes, FLT3, IL7R, SH2B3 and TSLP – Poor prognosis (especially when with IKZF1 deletions) – Therapies targeting JAK-STAT, PI3K/mTOR, and BCL2 signaling show efficacy in preclincal models DUX4- and ERG-deregulated ALL • DUX4/IGH – DUX4 is not expressed in normal B cells – t(4;14)(q35;q32): truncated DUX4 is expressed when translocated to IGH – Truncated DUX4 interact with ERG and produce altered ERG • DUX4/ERG – Truncated ERG is expressed, which inhibits wild-type ERG transcriptional activity, and is transforming. – Favorable outcome, despite concomitant genetic alterations with poor outcomes (e.g. IKZF1, 40% of cases) – t(4;21)(q35;q22): not evident on karyotypic analysis but can be identified by sequencing MEF2D and ZNF384 gene fusions • MEF2D rearrangements – 3~4% of pediatric and 6~7% of adult ALLs – Rearranged to BCL9, HNRNPUL1, SS18, FOXJ2, CSF1R, and DAZAP1 – Older age of onset – Aberrant immunophenotype (CD10-, CD38+) – Poor outcome – Sensitivive to HDAC inhibitors (panobinostat) • ZNF384 rearrangements – Rearranged to EP300, CREBBP, TAF15, SYNRG, EWSR1, TCF3, and ARID1B – Often biphenotypic (B/myeloid) – Up-regulation of JAK/STAT pathway Mutations in relapsed ALL • CREBBP – ~20% of relapsed ALLs – Impair sensitivity to glucocorticoid therapy • NT5C2 – Resistance to purine analogs • MSH6 (mismatch repair) • NR3C1 (glucocorticoid receptor) • SETD2 (H3K36 trimethyltransferase) • KDM6 (lysine-specific demethylase) • MLL2 (epigenetic regulator) • Ras pathway mutations (e.g., KRAS, NRAS, FLT3, PTPN11) Gene mutations in B-ALL Pathway Gene Frequency (%) RAS signaling NRAS 17 KRAS 16 FLT3 7 PTPN11 5 NF1 3 B-cell differentiation PAX5 15 IKZF1 3 JAK/STAT signaling JAK1 2 JAK2 9 TP53/RB1 pathway TP53 4 RB1 1 CDKN2A/CDKN2B 1 Others TBL1XR1 2 ETV6 4 CREBBP 2 Unknown genes 9 Key genetic subtypes of T-ALL Translocation in T-ALL • 14q11 translocation (TCRA, TCRD, TCRB locus) – ~ 50% of T-ALLs – Juxtaposing transcription factor genes, such as TAL1, TAL2, LYL1, OLIG2, LMO1, LMO2, TLX1 (HOX11), TLX3 (HOX11L2), NKX2-1, NKX2-2, NKX2-5, HOXA genes, MYC, and MYB. • STIL-TAL1 fusion – Submicroscopic deletions fuses the promoter of STIL to TAL1 to induce an abnormal expression of TAL1 – ~25% of T-ALL patients • Cryptic rearrangements of ABL1 (NUP214-ABL1, EML1-ABL1, and ETV6-ABL1) – Possible candidate for TKI therapy Gene mutations in T-ALL Pathway Gene Frequency (%) Cell cycle defects CDKN2A/CDKN2B 96 TP53, RB, p27 4 Differentiation impairment TAL1, LMO1/2 39 LYL, LMO2 20 TLX1 7 TLX3 20 HOXA10/11 7 PICALM-MLLT10 5-10 MLL-fusions 4 TAL2 1 Proliferation and survival ABL1-fusions 8 NRAS 5 FLT3 5 LCK 1 ETV6-PBL2, ETV6-JAK2 1 PTEN 1 Self-renewal capacity NOTCH1, FBXW7 56 Pathways deregulated in T-ALL JAK-STAT Ras/PI3K/AKT NOTCH IL7R, JAK1, JAK3, STAT5B NRAS, KRAS, PTEN NOTCH1, FBXW7 Transcription Epigenetic mRNA/ribosome regulator PHF6, SUZ12, EZH2, TET2, CNOT3, RPL5, RPL10 H3F3A, KDM6A LEF1, WT1, BCL11B, ZEB2 Early T-cell Phenytpe (ETP)-ALL Coustan-Smith et al. Lancet 2009; Neumann et al. Blood 2013 Super-enhancer mutation in T-ALL Mansour et al. Science 2014 Goossens et al. Blood 2017 Germ-line predisposition to ALL Stieglitz et al. Therapeutic Advances in Hematology 2013 Clinical Utility of NGS Testing in Acute Leukemias • Diagnosis – Molecular classification (WHO 2016) Recurrent translocation Gene mutation – Precedent disorders Predisposing syndromes • Prognostic risk stratification • Eligibility for targeted therapy • Minimal residual disease (MRD) monitoring NGS panel for ALL (185 genes) B-ALL T-ALL NRAS, KRAS, FLT3, PTPN11, CDKN2A/B, TAL1, LMO1/2, PAX5, IKZF1, JAK2, CREBBP, TLX1, TLX3, NOTCH1, TP53, CDKN2A, etc. etc. ABL1, ABL2, CRLF2, CSF1R, EPOR, ETV6, JAK2, KMT2A, PDGFRB, STIL, TCF3 rearrangements Fusion genes 11 partner genes Validation for ALL panel • 83 patients with ALL – 33 children – 28 adolescent and young adult (AYA) – 22 adults • Classification – 71 B-ALL – 12 T-ALL • Bone marrow samples at initial diagnosis (or in relapse) – Blast > 50% Raw data Bioinformatics pipeline in Align & mapping (BWA) Severance Realignment (GATK) Hospital Normalized GATK Mutect, Varscan IGV Pindel Delly ExomeDepth Custom depth Insertion/ Transloc Genic CNVs Chromosomal Annovar VEP deletion) ation (crosscheck) CNVs SNVs (crosscheck & filtering) In silico Database, literature search (Alamut, HGMD, COSMIC) Oncogenic, likely oncogenic, VUS Correlation with clinical findings Consensus discussion Confirmation (Sanger sequencing, MLPA, microarray) Final report Copy number analysis by read-depth comparison B-ALL • 1.6 (113/71) mutations per patient • 24 patients (33.8%) did not have oncogenic mutation • 45/113 mutations (39.8%) are copy number variations T-ALL • 3.9 (47/12) mutations per patient • All patients had oncogenic mutations • 16/47 mutations (34.0%) are copy number variations A case with ETV6/RUNX1 translocation A case with hyperdiploidy Chromosomal CNVs Off-target analysis On-target DNA Probe Off-target DNA Wash-out ALL with hyperdiploidy Chromosomal CNVs identified by NGS #1 aneuploidy: -2,+6,+7,-8,-16 #29 5q+, 7p-, 9p-,13q-, 15q-, 21?, X? #2 interstitial deletion: 5,6,9,10,19 #30 -9, 17p13.3p11.2-, 1711.2q25.3+,21q11.2122.2+, -X #3 deletion: 1p22.3q21.1, 2q34q36.3, 5q21.1q32, 11q14.2q23.1 #31 5q33.2 interstitial deletion #4 +7p #32 9p21.3p13.2 deletion #5 +17,19,21 #33 11q+, Xq+ #6 deletion: 5q14.3q35.3, 12p13.33p12.2, duplication: 13q21.33q34 #34 hyperdiploidy: +4,+8, +14, +16,+17,+18, +21,+X #7 gain: 4q22q35, 5p15q14, loss: 5q21q35, 21q22, Xp11q28 #35 -7 #8 +12,+20 #36 -7 #9 9p- #37 high hyperdipolidy: 1q+, 4+, 6+, 9+,10+,14+, 17+, 18+, 21+ #10 13q+. 17q- #38 high hyperdipoidy: 3q+, 6+, 10+, 13p-, 14+17+, 21+, X+ #11 +14 #39 17q21q23 duplication #12 +5,+6,+8,+14,+17,+18,+21,+22 #40 6q-, Xq+ #13 12p+.12p- #41 gain: 4,6p,9, 14, 17, 18, 21, X #14 17p-, 22+ #42 ?7p-, +10,+14,+17,+21 #15 9p-,11p- #43 4q22.1q28.3-, 9p24.3p13.3-, 16p12.1q13- #16 +18,+21,+X #44 13q13.3q14.3 deletion #17 +6,+14,+21,+X #45 1q+,16q- #18 8q+,11q- #46 -7,-15,-21 #19 +8, 9p-, 20q-, 21+ #47 +6,+10,+14,+21,+X #20 +21(c?) #48 +4,+6,8q+,+14,+17,+18,+21,+X #21 1q+, 13q-, 17q+,21+ #49 7p-, 9q+, 12q interstitial deletion #22 High hyperdipoidy: +2,+4,+6,+10,+14,+21 #50 8p23p22-, 9p24q22- #23 9p-,12p- #51 gain: 4,6,8, 10, 11,14,18, 21,X #24 aneuploidy #52 loss: 12p13.3p13.1, 13q13q34, gain:17p13.3p13.2 #25 high hyperdiploidy: +4,+6,+8,+10,+17,+18,+21 #53 6q15q23.2- #26 1,13,16,21,22 #54 +8, 9p21p13.2-,+21 #27 8,14,17,21 #55 +21 +X #28 1q+, 4p-,8p-,17p-,17p+, 21++ #56 interstitial deletion: 2 6 Algorithms to detect translocations Probes directed to intronic breakpoints Case Age Type RT-PCR / RNA-Seq DNA algorithm (Delly) Detection of 6 51 B-ALL BCR-ABL1 Detected translocation by 16 15 B-ALL BCR-ABL1 Detected 17 25 B-ALL BCR-ABL1 Not detected DNA sequencing 26 52 B-ALL BCR-ABL1 Not detected 31 16 B-ALL BCR-ABL1 Detected 32 40 B-ALL BCR-ABL1 Detected 35 33 B-ALL BCR-ABL1 Detected • 17/27 (62.9%) 54 73 B-ALL BCR-ABL1 Detected transclocaitons could be 61 64 B-ALL BCR-ABL1 Not detected detected by DNA 62 76 B-ALL BCR-ABL1 Not detected 66 22 B-ALL BCR-ABL1 Not detected sequencing 68 46 B-ALL BCR-ABL1 Detected 69 73 B-ALL BCR-ABL1 Detected 70 72 B-ALL BCR-ABL1 Detected 101 58 B-ALL BCR-ABL1 Detected 5 10 B-ALL ETV6/RUNX1 Detected 3 4 B-ALL ETV6-RUNX1 Detected 13 8 B-ALL ETV6-RUNX1 Detected 25 3 B-ALL ETV6-RUNX1 Detected 28 3 B-ALL ETV6-RUNX1 Not detected 45 3 B-ALL ETV6-RUNX1 Not detected 46 5 B-ALL ETV6-RUNX1 Not detected 78 3 B-ALL ETV6-RUNX1 Detected 80 2 B-ALL ETV6-RUNX1 Detected 7 0 B-ALL KMT2A-AFF1 Detected 85 17 B-ALL P2Y8R-CRLF2 Not detected 84 5 B-ALL PAX5-CBFA2T3, P2RY8R-CRLF2 Not detected Difficulties in targeting introns • Breakpoints occur in introns which are difficult to capture due to repeat regions and variable GC content. Abel et al. J Mol Diagn. 2014 Detection of RNA fusion by NGS Detection of RNA fusion by NGS (Illumina TruSight, ArcherDx Fuxion Plex) ID HemaVision Chromosome Illumina TruSight RNA, ArcherDx Fusion Plex 1 b3a2, Major BCR-ABL1 46,XY,t(9;22)(q34;q11.2)[20] BCR-ABL1 rsa(22;9)(q11.23;q34.12) ABL1-BCR rsa(9;22)(q34.12;q11.23) 2 b3a2, Major BCR-ABL1 46,XY,t(9;22)(q34;q11.2)[20] BCR-ABL1 rsa(22;9)(q11.23;q34.12) ABL1-BCR rsa(9;22)(q34.12;q11.23) 3 b3a2, Major BCR-ABL1 46,XY,t(9;22)(q34;q11.2)[21] BCR-ABL1 rsa(22;9)(q11.23;q34.12) BCR-ABL1
Load more

Recommended publications
  • Down-Regulation of Stem Cell Genes, Including Those in a 200-Kb Gene Cluster at 12P13.31, Is Associated with in Vivo Differentiation of Human Male Germ Cell Tumors
    Research Article Down-Regulation of Stem Cell Genes, Including Those in a 200-kb Gene Cluster at 12p13.31, Is Associated with In vivo Differentiation of Human Male Germ Cell Tumors James E. Korkola,1 Jane Houldsworth,1,2 Rajendrakumar S.V. Chadalavada,1 Adam B. Olshen,3 Debbie Dobrzynski,2 Victor E. Reuter,4 George J. Bosl,2 and R.S.K. Chaganti1,2 1Cell Biology Program and Departments of 2Medicine, 3Epidemiology and Biostatistics, and 4Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York Abstract on the degree and type of differentiation (i.e., seminomas, which Adult male germ cell tumors (GCTs) comprise distinct groups: resemble undifferentiated primitive germ cells, and nonseminomas, seminomas and nonseminomas, which include pluripotent which show varying degrees of embryonic and extraembryonic embryonal carcinomas as well as other histologic subtypes patterns of differentiation; refs. 2, 3). Nonseminomatous GCTs are exhibiting various stages of differentiation. Almost all GCTs further subdivided into embryonal carcinomas, which show early show 12p gain, but the target genes have not been clearly zygotic or embryonal-like differentiation, yolk sac tumors and defined. To identify 12p target genes, we examined Affymetrix choriocarcinomas, which exhibit extraembryonal forms of differ- (Santa Clara, CA) U133A+B microarray (f83% coverage of 12p entiation, and teratomas, which show somatic differentiation along genes) expression profiles of 17 seminomas, 84 nonseminoma multiple lineages (3). Both seminomas and embryonal carcinoma GCTs, and 5 normal testis samples. Seventy-three genes on 12p are known to express stem cell markers, such as POU5F1 (4) and were significantly overexpressed, including GLUT3 and REA NANOG (5).
    [Show full text]
  • Supplemental Materials ZNF281 Enhances Cardiac Reprogramming
    Supplemental Materials ZNF281 enhances cardiac reprogramming by modulating cardiac and inflammatory gene expression Huanyu Zhou, Maria Gabriela Morales, Hisayuki Hashimoto, Matthew E. Dickson, Kunhua Song, Wenduo Ye, Min S. Kim, Hanspeter Niederstrasser, Zhaoning Wang, Beibei Chen, Bruce A. Posner, Rhonda Bassel-Duby and Eric N. Olson Supplemental Table 1; related to Figure 1. Supplemental Table 2; related to Figure 1. Supplemental Table 3; related to the “quantitative mRNA measurement” in Materials and Methods section. Supplemental Table 4; related to the “ChIP-seq, gene ontology and pathway analysis” and “RNA-seq” and gene ontology analysis” in Materials and Methods section. Supplemental Figure S1; related to Figure 1. Supplemental Figure S2; related to Figure 2. Supplemental Figure S3; related to Figure 3. Supplemental Figure S4; related to Figure 4. Supplemental Figure S5; related to Figure 6. Supplemental Table S1. Genes included in human retroviral ORF cDNA library. Gene Gene Gene Gene Gene Gene Gene Gene Symbol Symbol Symbol Symbol Symbol Symbol Symbol Symbol AATF BMP8A CEBPE CTNNB1 ESR2 GDF3 HOXA5 IL17D ADIPOQ BRPF1 CEBPG CUX1 ESRRA GDF6 HOXA6 IL17F ADNP BRPF3 CERS1 CX3CL1 ETS1 GIN1 HOXA7 IL18 AEBP1 BUD31 CERS2 CXCL10 ETS2 GLIS3 HOXB1 IL19 AFF4 C17ORF77 CERS4 CXCL11 ETV3 GMEB1 HOXB13 IL1A AHR C1QTNF4 CFL2 CXCL12 ETV7 GPBP1 HOXB5 IL1B AIMP1 C21ORF66 CHIA CXCL13 FAM3B GPER HOXB6 IL1F3 ALS2CR8 CBFA2T2 CIR1 CXCL14 FAM3D GPI HOXB7 IL1F5 ALX1 CBFA2T3 CITED1 CXCL16 FASLG GREM1 HOXB9 IL1F6 ARGFX CBFB CITED2 CXCL3 FBLN1 GREM2 HOXC4 IL1F7
    [Show full text]
  • Supplementary Data
    SUPPLEMENTARY DATA A cyclin D1-dependent transcriptional program predicts clinical outcome in mantle cell lymphoma Santiago Demajo et al. 1 SUPPLEMENTARY DATA INDEX Supplementary Methods p. 3 Supplementary References p. 8 Supplementary Tables (S1 to S5) p. 9 Supplementary Figures (S1 to S15) p. 17 2 SUPPLEMENTARY METHODS Western blot, immunoprecipitation, and qRT-PCR Western blot (WB) analysis was performed as previously described (1), using cyclin D1 (Santa Cruz Biotechnology, sc-753, RRID:AB_2070433) and tubulin (Sigma-Aldrich, T5168, RRID:AB_477579) antibodies. Co-immunoprecipitation assays were performed as described before (2), using cyclin D1 antibody (Santa Cruz Biotechnology, sc-8396, RRID:AB_627344) or control IgG (Santa Cruz Biotechnology, sc-2025, RRID:AB_737182) followed by protein G- magnetic beads (Invitrogen) incubation and elution with Glycine 100mM pH=2.5. Co-IP experiments were performed within five weeks after cell thawing. Cyclin D1 (Santa Cruz Biotechnology, sc-753), E2F4 (Bethyl, A302-134A, RRID:AB_1720353), FOXM1 (Santa Cruz Biotechnology, sc-502, RRID:AB_631523), and CBP (Santa Cruz Biotechnology, sc-7300, RRID:AB_626817) antibodies were used for WB detection. In figure 1A and supplementary figure S2A, the same blot was probed with cyclin D1 and tubulin antibodies by cutting the membrane. In figure 2H, cyclin D1 and CBP blots correspond to the same membrane while E2F4 and FOXM1 blots correspond to an independent membrane. Image acquisition was performed with ImageQuant LAS 4000 mini (GE Healthcare). Image processing and quantification were performed with Multi Gauge software (Fujifilm). For qRT-PCR analysis, cDNA was generated from 1 µg RNA with qScript cDNA Synthesis kit (Quantabio). qRT–PCR reaction was performed using SYBR green (Roche).
    [Show full text]
  • The Forkhead Transcription Factor FOXM1 Promotes Endocrine
    Bergamaschi et al. Breast Cancer Research 2014, 16:436 http://breast-cancer-research.com/content/16/5/436 RESEARCH ARTICLE Open Access The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor–positive breast cancer by expansion of stem-like cancer cells Anna Bergamaschi1, Zeynep Madak-Erdogan1, Yu Jin Kim2, Yoon-La Choi2,3, Hailing Lu1,4 and Benita S Katzenellenbogen1* Abstract Introduction: The forkhead transcription factor FOXM1 coordinates expression of cell cycle–related genes and plays a pivotal role in tumorigenesis and cancer progression. We previously showed that FOXM1 acts downstream of 14-3-3ζ signaling, the elevation of which correlates with a more aggressive tumor phenotype. However, the role that FOXM1 might play in engendering resistance to endocrine treatments in estrogen receptor–positive (ER+) patients when tumor FOXM1 is high has not been clearly defined yet. Methods: We analyzed FOXM1 protein expression by immunohistochemistry in 501 ER-positive breast cancers. We also mapped genome-wide FOXM1, extracellular signal-regulated kinase 2 and ERα binding events by chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq) in hormone-sensitive and resistant breast cancer cells after tamoxifen treatment. These binding profiles were integrated with gene expression data derived from cells before and after FOXM1 knockdown to highlight specific FOXM1 transcriptional networks. We also modulated the levels of FOXM1 and newly discovered FOXM1-regulated genes and examined their impact on the cancer stem-like cell population and on cell invasiveness and resistance to endocrine treatments. Results: FOXM1 protein expression was high in 20% of the tumors, which correlated with significantly reduced survival in these patients (P = 0.003 by logrank Mantel-Cox test).
    [Show full text]
  • Grimme, Acadia.Pdf
    MECHANISM OF ACTION OF HISTONE DEACETYLASE INHIBITORS ON SURVIVAL MOTOR NEURON 2 PROMOTER by Acadia L. Grimme A thesis submitted to the Faculty of the University of Delaware in partial fulfillment of the requirements for the degree of Bachelors of Science in Biological Sciences with Distinction Spring 2018 © 2018 Acadia Grimme All Rights Reserved MECHANISM OF ACTION OF HISTONE DEACETYLASE INHIBITORS ON SURVIVAL MOTOR NEURON 2 PROMOTER by Acadia L. Grimme Approved: __________________________________________________________ Matthew E. R. Butchbach, Ph.D. Professor in charge of thesis on behalf of the Advisory Committee Approved: __________________________________________________________ Deni S. Galileo, Ph.D. Professor in charge of thesis on behalf of the Advisory Committee Approved: __________________________________________________________ Carlton R. Cooper, Ph.D. Committee member from the Department of Biological Sciences Approved: __________________________________________________________ Gary H. Laverty, Ph.D. Committee member from the Board of Senior Thesis Readers Approved: __________________________________________________________ Michael Chajes, Ph.D. Chair of the University Committee on Student and Faculty Honors ACKNOWLEDGMENTS I would like to acknowledge my thesis director Dr. Butchbach for his wonderful guidance and patience as I worked through my project. He has been an excellent research mentor over the last two years and I am forever thankful that he welcomed me into his lab. His dedication to his work inspires me as an aspiring research scientist. His lessons will carry on with me as I pursue future research in graduate school and beyond. I would like to thank both current and former members of the Motor Neuron Disease Laboratory: Sambee Kanda, Kyle Hinkle, and Andrew Connell. Sambee and Andrew patiently taught me many of the techniques I utilized in my project, and without them it would not be what it is today.
    [Show full text]
  • Using Viper, a Package for Virtual Inference of Protein-Activity by Enriched Regulon Analysis
    Using viper, a package for Virtual Inference of Protein-activity by Enriched Regulon analysis Mariano J. Alvarez1,2, Federico M. Giorgi1, and Andrea Califano1 1Department of Systems Biology, Columbia University, 1130 St. Nicholas Ave., New York 2DarwinHealth Inc, 3960 Broadway, New York April 30, 2018 1 Overview of VIPER Phenotypic changes effected by pathophysiological events are now routinely captured by gene expression pro- file (GEP) measurements, determining mRNA abundance on a genome-wide scale in a cellular population[8, 9]. In contrast, methods to measure protein abundance on a proteome-wide scale using arrays[11] or mass spectrometry[10] technologies are far less developed, covering only a fraction of proteins, requiring large amounts of tissue, and failing to directly capture protein activity. Furthermore, mRNA expression does not constitute a reliable predictor of protein activity, as it fails to capture a variety of post-transcriptional and post-translational events that are involved in its modulation. Even reliable measurements of protein abundance, for instance by low-throughput antibody based methods or by higher-throughput methods such as mass spectrometry, do not necessarily provide quantitative assessment of functional activity. For instance, enzymatic activity of signal transduction proteins, such as kinases, ubiquitin ligases, and acetyltransferases, is frequently modulated by post-translational modification events that do not affect total protein abundance. Similarly, transcription factors may require post-translationally mediated activation, nuclear translocation, and co-factor availability before they may regulate specific repertoires of their transcriptional targets. Fi- nally, most target-specific drugs affect the activity of their protein substrates rather than their protein or mRNA transcript abundance.
    [Show full text]
  • Abnormal Expression of Forkhead Box J2 (FOXJ2) Suppresses Migration and Invasion in Extrahepatic Cholangiocarcinoma and Is Associated with Prognosis
    INTERNATIONAL JOURNAL OF ONCOLOGY 46: 2449-2458, 2015 Abnormal expression of Forkhead Box J2 (FOXJ2) suppresses migration and invasion in extrahepatic cholangiocarcinoma and is associated with prognosis YONG QIANG1,2*, FEIRAN WANG1*, SUJUAN YAN3, Haitao ZHANG4, LIRONG ZHU1, ZHEN CHEN1, FANG TU5, DONGZHI WANG1, GANG WANG1, WEI WANG1 and ZHONG CHEN1 1Department of Hepatobiliary Surgery, Affiliated Hospital of Nantong University and Research Institute of Hepatobiliary Surgery of Nantong University, Nantong, Jiangsu 226001; Departments of 2General Surgery and 3Gynaecology and Obstetrics, The First People's Hospital of Jingmen, Dongbao District, Jingmen, Hubei 448000; 4Jiangsu Key Laboratory of Neuroregeneration, Nantong University, Nantong, Jiangsu 226001; 5Department of Operating Rooms, Shayang People's Hospital, Shayang, Hubei 448200, P.R. China Received February 2, 2015; Accepted March 30, 2015 DOI: 10.3892/ijo.2015.2957 Abstract. Extrahepatic cholangiocarcinoma (CC) is an aggres- samples. Overexpression FOXJ2 expression markedly inhibited sive malignancy with dismal prognosis and characterized cell proliferation, migration and invasion in vitro. FOXJ2 is a by early invasion, metastasis and postoperative recurrence. transcription factor that has been reported to induce epithelial- Therefore, understanding the main molecular mechanisms of mesenchymal transition (EMT). These findings indicated that this malignancy is the key for the development of novel and FOXJ2 gene played a tumor suppressor role in extrahepatic effective therapeutic strategies
    [Show full text]
  • Transcription Factor Footprinting Using Chromatin Accessibility Data And
    Downloaded from genome.cshlp.org on October 6, 2021 - Published by Cold Spring Harbor Laboratory Press TRACE: transcription factor footprinting using chromatin accessibility data and DNA sequence Ningxin Ouyang1 and Alan P. Boyle1,2* 1Department of Computational Medicine and Bioinformatics, 2Department of Human Genetics University of Michigan, Ann Arbor, MI, 48109 * To whom correspondence should be addressed: Alan P. Boyle, Ph.D. Department of Computational Medicine and Bioinformatics University of Michigan Medical School 2049A Palmer Commons 100 Washtenaw Ave. Ann Arbor, MI 48109 [email protected] Keywords: Gene regulation, Transcription factors, Footprinting, TFBSs, Machine learning Downloaded from genome.cshlp.org on October 6, 2021 - Published by Cold Spring Harbor Laboratory Press Abstract Transcription is tightly regulated by cis-regulatory DNA elements where transcription factors can bind. Thus, identification of transcription factor binding sites (TFBSs) is key to understanding gene expression and whole regulatory networks within a cell. The standard approaches used for TFBS prediction, such as position weight matrices (PWMs) and chromatin immunoprecipitation followed by sequencing (ChIP- seq), are widely used, but have their drawbacks including high false positive rates and limited antibody availability, respectively. Several computational footprinting algorithms have been developed to detect TFBSs by investigating chromatin accessibility patterns, however these also have limitations. We have developed a footprinting method to predict Transcription factor footpRints in Active Chromatin Elements (TRACE) to improve the prediction of TFBS footprints. TRACE incorporates DNase-seq data and PWMs within a multivariate Hidden Markov Model (HMM) to detect footprint-like regions with matching motifs. TRACE is an unsupervised method that accurately annotates binding sites for specific TFs automatically with no requirement for pre-generated candidate binding sites or ChIP-seq training data.
    [Show full text]
  • Predict AID Targeting in Non-Ig Genes Multiple Transcription Factor
    Downloaded from http://www.jimmunol.org/ by guest on September 26, 2021 is online at: average * The Journal of Immunology published online 20 March 2013 from submission to initial decision 4 weeks from acceptance to publication Multiple Transcription Factor Binding Sites Predict AID Targeting in Non-Ig Genes Jamie L. Duke, Man Liu, Gur Yaari, Ashraf M. Khalil, Mary M. Tomayko, Mark J. Shlomchik, David G. Schatz and Steven H. Kleinstein J Immunol http://www.jimmunol.org/content/early/2013/03/20/jimmun ol.1202547 Submit online. Every submission reviewed by practicing scientists ? is published twice each month by http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://www.jimmunol.org/content/suppl/2013/03/20/jimmunol.120254 7.DC1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 26, 2021. Published March 20, 2013, doi:10.4049/jimmunol.1202547 The Journal of Immunology Multiple Transcription Factor Binding Sites Predict AID Targeting in Non-Ig Genes Jamie L. Duke,* Man Liu,†,1 Gur Yaari,‡ Ashraf M. Khalil,x Mary M. Tomayko,{ Mark J. Shlomchik,†,x David G.
    [Show full text]
  • Development and Utilization of Human Decidualization Reporter Cell Line Uncovers New Modulators of Female Fertility
    Development and utilization of human decidualization reporter cell line uncovers new modulators of female fertility Meade Hallera,1, Yan Yina,1, and Liang Maa,2 aDepartment of Internal Medicine, Division of Dermatology, Washington University in St. Louis, St. Louis, MO 63110 Edited by R. Michael Roberts, University of Missouri, Columbia, MO, and approved August 19, 2019 (received for review May 2, 2019) Failure of embryo implantation accounts for a significant percent- Decidualization involves the rapid proliferation, then differ- age of female infertility. Exquisitely coordinated molecular pro- entiation of fibroblast-like endometrial stromal cells into epithelioid- grams govern the interaction between the competent blastocyst like decidual cells, some of which become large and polyploid or and the receptive uterus. Decidualization, the rapid proliferation multinuclear. These cells become part of the decidual tissue that and differentiation of endometrial stromal cells into decidual cells, surrounds the implanting conceptus (2, 9). The maternal de- is required for implantation. Decidualization defects can cause cidual tissue plays a crucial role in the establishment of preg- poor placentation, intrauterine growth restriction, and early nancy (11, 12). Accompanying the transformation of uterine parturition leading to preterm birth. Decidualization has not yet stromal cells to decidual cells are changes occurring in the en- been systematically studied at the genetic level due to the lack of a dometrium that include extensive extracellular matrix remodel- suitable high-throughput screening tool. Herein we describe the ing, vascular remodeling, angiogenesis, and apoptosis. While generation of an immortalized human endometrial stromal cell line these are happening, the conceptus enlarges and placental de- that uses yellow fluorescent protein under the control of the prolactin velopment occurs (2, 9).
    [Show full text]
  • A Meta-Analysis of the Effects of High-LET Ionizing Radiations in Human Gene Expression
    Supplementary Materials A Meta-Analysis of the Effects of High-LET Ionizing Radiations in Human Gene Expression Table S1. Statistically significant DEGs (Adj. p-value < 0.01) derived from meta-analysis for samples irradiated with high doses of HZE particles, collected 6-24 h post-IR not common with any other meta- analysis group. This meta-analysis group consists of 3 DEG lists obtained from DGEA, using a total of 11 control and 11 irradiated samples [Data Series: E-MTAB-5761 and E-MTAB-5754]. Ensembl ID Gene Symbol Gene Description Up-Regulated Genes ↑ (2425) ENSG00000000938 FGR FGR proto-oncogene, Src family tyrosine kinase ENSG00000001036 FUCA2 alpha-L-fucosidase 2 ENSG00000001084 GCLC glutamate-cysteine ligase catalytic subunit ENSG00000001631 KRIT1 KRIT1 ankyrin repeat containing ENSG00000002079 MYH16 myosin heavy chain 16 pseudogene ENSG00000002587 HS3ST1 heparan sulfate-glucosamine 3-sulfotransferase 1 ENSG00000003056 M6PR mannose-6-phosphate receptor, cation dependent ENSG00000004059 ARF5 ADP ribosylation factor 5 ENSG00000004777 ARHGAP33 Rho GTPase activating protein 33 ENSG00000004799 PDK4 pyruvate dehydrogenase kinase 4 ENSG00000004848 ARX aristaless related homeobox ENSG00000005022 SLC25A5 solute carrier family 25 member 5 ENSG00000005108 THSD7A thrombospondin type 1 domain containing 7A ENSG00000005194 CIAPIN1 cytokine induced apoptosis inhibitor 1 ENSG00000005381 MPO myeloperoxidase ENSG00000005486 RHBDD2 rhomboid domain containing 2 ENSG00000005884 ITGA3 integrin subunit alpha 3 ENSG00000006016 CRLF1 cytokine receptor like
    [Show full text]
  • Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6 Atish D
    Published OnlineFirst November 29, 2016; DOI: 10.1158/0008-5472.CAN-16-0455 Cancer Tumor and Stem Cell Biology Research Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6 Atish D. Choudhury1,2,3, Anna C. Schinzel1,3, Maura B. Cotter1, Rosina T. Lis1,4, Katherine Labella1, Ying Jie Lock1, Francesca Izzo1,3, Isil Guney1,2, Michaela Bowden1, Yvonne Y. Li1, Jinal Patel3, Emily Hartman3, Steven A. Carr3, Monica Schenone3, Jacob D. Jaffe3, Philip W. Kantoff1,2, Peter S. Hammerman1,2,3, and William C. Hahn1,2,3 Abstract In prostate cancer, the development of castration resistance castration in a mouse xenograft model system. Tumors in is pivotal in progression to aggressive disease. However, which castration resistance was conferred by NEK6 were understanding of the pathways involved remains incomplete. predominantly squamous in histology with no evidence of In this study, we performed a high-throughput genetic screen AR signaling. Gene expression profiling suggested that NEK6 to identify kinases that enable tumor formation by androgen- overexpression stimulated cytoskeletal, differentiation, and dependent prostate epithelial (LHSR-AR) cells under andro- immune signaling pathways and maintained gene expression gen-deprived conditions. In addition to the identification of patterns normally decreased by castration. Phosphoproteome known mediators of castration resistance, which served to profiling revealed the transcription factor FOXJ2 as a novel validate the screen, we identified a mitotic-related serine/ NEK6 substrate, with FOXJ2 phosphorylation associated with threonine kinase, NEK6, as a mediator of androgen-indepen- increased expression of newly identified NEK6 transcriptional dent tumor growth. NEK6 was overexpressed in a subset targets.
    [Show full text]